Rogado, Jacobo http://orcid.org/0000-0002-9795-8762
Pozo, Fernando
Troulé, Kevin
Sánchez-Torres, José Miguel
Romero-Laorden, Nuria
Mondejar, Rebeca
Donnay, Olga
Ballesteros, Anabel
Pacheco-Barcia, Vilma
Aspa, Javier
Al-Shahrour, Fátima
Alfranca, Arantzazu
Colomer, Ramon
Funding for this research was provided by:
Instituto de Salud Carlos III (PIE15/00068, PI17/01865, PI19/01491, PI17/00801, PI21/01111, JR17/00007, RETOS RTI2018-097596-B-I00 (AEI/10.13039/501100011033 MCI / FEDER, UE))
Fundación Científica Asociación Española Contra el Cáncer (Molecular analysis of the Exhaled Breath Condensate in the management of solitary pulmonary nodule)
Article History
Received: 19 May 2022
Accepted: 5 July 2022
First Online: 23 July 2022
Declarations
:
: Jacobo Rogado reports personal fees from Roche, AstraZeneca, Merck, Ferrer, Persan Farma, Fresenius Kabi, travel expenses from MSD, BMS, Roche, AstraZeneca and advisor consultancies from Fresenius Kabi. Nuria Romero reports advisory consultancies from Ipsen, Janssen, Clovis, AstraZeneca and research funding from Janssen, MSD and Pfizer. Ramon Colomer reports research funding from Roche, Janssen, BMS, and MSD. All the declared conflict of interests are outside the submitted work. All the other authors have no conflicts to declare.
: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Hospital Universitario La Princesa on 22 December 2016 under the code 2918.
: Informed consent was obtained from all patients involved in the study.